abstract |
Inhibitory oligonucleotide having the general formula: (I) are disclosed which can be used in pharmaceutical compositions, whereby in formula (I) C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar, 2'-0-methylcytidine, 5-bromocytidine, 5-hydroxycytidine, ribocytidine and cytosine-P-D-arabinofuranoside, G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine, a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base and the guanosine nucleoside sugar, X 1 and X 3 is any nucleotide sequence with 0 to 12 bases and each nucleotide is independent of any other, X 2 is any nucleotide sequence having 0 to 3 nucleotides, N 2 and N 3 are each independently any nucleotide, N 4 and N 7 is a pyrimidine or a modified pyrimidine, N 5 is a purin or a modified purin, N 6 is a modified pyrimidine, A or a modified purin, wherein at least two of the nucleotides N 4 , N 5 , N 6 or N 7 are modified purins or modified pyrimidines. |